Vir Biotechnology (VIR) Net Equity Issued and Repurchased (2018 - 2026)

Vir Biotechnology (VIR) reported Net Equity Issued and Repurchased of $162.3 million for Q1 2026, up 290.52% sequentially from -$85.2 million in Q4 2021.

Vir Biotechnology (VIR) Net Equity Issued and Repurchased (2018 - 2026) Analysis & Trends

Vir Biotechnology (VIR) has 5 years of Net Equity Issued and Repurchased data on file, last reported at $162.3 million in Q1 2026.

  • For the quarter ending Q1 2026, Net Equity Issued and Repurchased changed N/A year-over-year to $162.3 million; the trailing twelve-month figure through Mar 2026 stood at $77.1 million (up 190.52% YoY), and the FY2020 full-year result was $323.2 million, up 1.85% from the prior year.
  • Net Equity Issued and Repurchased advanced to $162.3 million in Q1 2026, from -$85.2 million in the prior quarter.
  • In the past five years, Net Equity Issued and Repurchased ranged from a high of $162.3 million in Q1 2026 to a low of $162.3 million in Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Equity Issued and Repurchased (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn -
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 163.10 Mn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - 141.90 Mn
10 Vir Biotechnology 1.38 Bn 1.38 Bn - 162.35 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 162.35 Mn
Mar 31, 2026 162.35 Mn
Dec 31, 2021 -85.21 Mn
Dec 31, 2021 -85.21 Mn
Mar 31, 2021 85.21 Mn
Mar 31, 2021 85.21 Mn
Sep 30, 2020 116.52 Mn
Sep 30, 2020 116.52 Mn
Jun 30, 2019 -7,000.00
Jun 30, 2019 -7,000.00
Mar 31, 2019 317.34 Mn
Mar 31, 2019 317.34 Mn
Dec 31, 2018 39,000.00
Dec 31, 2018 39,000.00